HC Wainwright Reiterates Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

HC Wainwright reaffirmed their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research note published on Friday,Benzinga reports. HC Wainwright currently has a $200.00 price target on the specialty pharmaceutical company’s stock.

Other equities analysts have also issued research reports about the stock. Royal Bank of Canada increased their price target on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a report on Wednesday, October 23rd. Piper Sandler reissued an “overweight” rating and issued a $163.00 target price (down previously from $166.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. JPMorgan Chase & Co. lifted their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research note on Monday, August 19th. Robert W. Baird increased their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $175.33.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $124.34 on Friday. The stock has a market cap of $7.52 billion, a price-to-earnings ratio of 18.17, a PEG ratio of 1.07 and a beta of 0.57. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The business has a 50-day simple moving average of $113.65 and a 200 day simple moving average of $110.73. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $134.17.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the sale, the chief executive officer now owns 428,976 shares in the company, valued at approximately $47,547,699.84. This trade represents a 0.23 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares in the company, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,110 shares of company stock valued at $720,160 in the last quarter. Company insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Versant Capital Management Inc increased its position in shares of Jazz Pharmaceuticals by 13,450.0% during the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 269 shares during the period. Itau Unibanco Holding S.A. purchased a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth approximately $29,000. EverSource Wealth Advisors LLC raised its position in shares of Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 97 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 116 shares during the period. Finally, Gladius Capital Management LP purchased a new position in shares of Jazz Pharmaceuticals in the 2nd quarter valued at approximately $33,000. 89.14% of the stock is currently owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.